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A major challenge exists in the preparation of scaﬀolds for bone regeneration, namely, achieving simul-
taneously bioactivity, biocompatibility, mechanical performance and simple manufacturing. Here, cell-
ulose nanoﬁbrils (CNF) are introduced for the preparation of scaﬀolds taking advantage of their biocom-
patibility and ability to form strong 3D porous networks from aqueous suspensions. CNF are made bio-
active for bone formation through a simple and scalable strategy that achieves highly interconnected 3D
networks. The resultant materials optimally combine morphological and mechanical features and facilitate
hydroxyapatite formation while releasing essential ions for in vivo bone repair. The porosity and roughness
of the scaﬀolds favor several cell functions while the ions act in the expression of genes associated with
cell diﬀerentiation. Ion release is found critical to enhance the production of the bone morphogenetic
protein 2 (BMP-2) from cells within the fractured area, thus accelerating the in vivo bone repair. Systemic
biocompatibility indicates no negative eﬀects on vital organs such as the liver and kidneys. The results
pave the way towards a facile preparation of advanced, high performance CNF-based scaﬀolds for bone
tissue engineering.
Introduction
Tissue engineering has allowed the introduction of functional
constructs for the regeneration of defective or lost biological
tissues.1,2 Recent eﬀorts have showed that three-dimensional,
highly porous polymer scaﬀolds are suitable to promote
cell functions, and consequently tissue regeneration.3–5
Specifically, practical implementation of such materials for
bone formation may involve the seeding of the patient’s own
cells within the scaﬀold, before implantation, or placing the
scaﬀold directly in the fracture (damaged) area to promote pro-
liferation of cells and in vivo growth.6,7 Regardless of the
approach employed, the scaﬀolds are of critical importance
since they directly aﬀect the attachment, diﬀerentiation and
maturation of cells as well as matrix formation for their survi-
val. Scaﬀolds must display high porosity and rough surfaces
combined with the necessary mechanical strength to support
the cells and to match the performance of the tissues at the
site of implantation. Additionally, they must bond chemically
with tissue.8
The design of scaﬀolds that combine the above-mentioned
characteristics can be achieved by “soft matter” engineering.
This has inspired recent research eﬀorts for the preparation of
scaﬀolds from polymers9–12 and bio-based colloids13–15 that
can be implemented in surgical procedures. In this respect,
nanocellulose presents a unique set of properties that includes
flexibility, mechanical strength and biocompatibility.16–20 In
fact, nanocellulose-based aero- and cryogels meet the micro-
structure and mechanical performance requirements of
scaﬀolds for tissue engineering.21 However, for use as bone
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tissue, a limiting factor in nanocellulose utilization is the lack
of bioactivity to induce bone regeneration. A recent eﬀort used
cellulose nanocrystal (CNC) aerogels to facilitate in vivo for-
mation of bone.22 Here, we propose cellulose nanofibrils
(CNF), which eﬀectively form networks in composites, to form
porous macrostructures that are able to grow and regenerate
bone by the addition of bioactive glass.23,24 Thus, the high
mechanical performance of the cellulose nanostructures is
combined with the bioactivity of the mineral component (con-
taining SiO2, CaO, Na2O, and P2O) to form an advanced bio-
medical composite. This strategy overcomes the two main
obstacles found in the individual use of these materials for
bone tissue engineering, namely, the absence of bioactivity in
nanocellulose and the brittleness of the bioactive glass and
the challenges it poses in manufacturing complex structures.
We exploit the synergies of such organic–inorganic compo-
sites, in which the cellulose nanofibrils act as a morphological
guide for nucleation and further biomineralization via reac-
tions involving the mineral phase of the bioactive glass in
contact with the physiological fluids. It is expected that the
glass phase not only allows the formation of hydroxyapatite
layers on the fibrils, favoring cell attachment, but also induces
the leaching of ions that are key to activate the expression of
osteogenic genes25,26 and stimulate angiogenesis.27–30
Results and discussion
The herein proposed scaﬀolds were prepared, without the
need for crosslinking, through a straightforward freeze-casting
protocol of colloidal aqueous suspensions of CNF containing
dispersed bioactive glass (Fig. 1a). A composite cryogel com-
prising ca. 80 wt% (dry basis) bioactive glass and 20 wt% (dry
basis) CNF, referred to as CC-Bio, is shown in Fig. S1.†
Although chiefly made up of brittle and fragile bioglass, the
composite cryogels preserve the intrinsic mouldable, charac-
teristics of CNF hydrogels and cryogels even after biominerali-
zation. The highly porous, interconnected structure of the cryo-
gels, a paramount characteristic in scaﬀold design, is evi-
denced by high-resolution X-ray micro-computed tomography
(µCT) imaging. We further discuss the formation of hydroxy-
apatite layers upon contact with simulated body fluid (SBF),
the kinetics of ion release from the composite cryogels, and
their cytocompatibility, putting emphasis on the importance
of these features for cell diﬀerentiation and bone formation.
Additionally, we perform in vivo tests using rat calvarial defect
models to provide a practical demonstration of the application
of the composite scaﬀolds in living organisms. Lastly, we show
that the obtained scaﬀolds do not negatively aﬀect vital organs
such as the kidneys and liver.
The composite CC-Bio cryogels, comprising an optimized
bioactive glass loading (see ESI Discussion S1 and Fig. S1†),
presented low density and extremely high strength, resisting
compressive loads over 1250 times their own weight (Fig. 1b).
The nanofibrils contributed with their highly percolated
assemblies that go beyond classical orthogonal contacts that
otherwise take place with stiﬀ building blocks.31 We com-
pared, by µCT imaging, the morphology of CC-Bio to that of
cryogels prepared with monolithic CNF, further referred to
as CC. Even if added at low mass fractions, CNF provided a
framework for the cryogel to form, owing to the highly
entangled fibrils.32 This led to freeze-cast porous structures
that corresponded to classical cellular materials (E ∼ ρ2),
similar to human bones.33 2D slices of the micro-tomograms
(Fig. 1e and f) highlight CC and CC-Bio cryogels with similar
morphological features, namely, porous networks intercon-
nected by macroscopic channels. These architectures are
expected to favor the infiltration of blood vessels, cell
migration, and nutrient transport.34 From the quantitative
morphological evaluation, it was confirmed that the bioactive
glass was deposited onto the surface of the fibrils, leading to
increased pore wall thickness from 33 ± 8 to 45 ± 11 µm (ESI
Discussion S2†). Therefore, lower densities of interlayer pores
and smaller pores were observed (Fig. S2†). Large pores were
apparent for CC (140 ± 44 µm) and CC-Bio (135 ± 33 µm)
(Fig. S3†), suitable for adhesion and proliferation of osteo-
blasts without cell aggregation35 and proper scaﬀold vasculari-
zation.36 The relatively smaller pores in CC-Bio influenced the
stress–strain profiles obtained from the uniaxial compression
of the cryogels (Fig. 1i and Fig. S1†), which revealed a plastic
regime for CC and CC-Bio that was initiated at strains of ca.
3.5 and 7%, respectively. The elastic regime of cellulose-based
cellular materials correlated with their porosity.21 Increased
cryogel compression strength, from 11 ± 1 to 24 ± 1 kPa, was
Fig. 1 (a) Schematic illustration of the preparation of composite cell-
ulose-based cryogels, CC-Bio, with the inset showing the characteristic
entangled contact points of CNF networks. (b) Photographs of CC-Bio
showing its characteristic light weight and high strength. X-ray microto-
mography images of (c and d) 3D reconstruction and (e and f) 2D slices
taken from the 3D images and their respective (g and h) X-ray projec-
tions. The images c, e, and g correspond to the pure cellulose cryogel
(CC), while d, f, and h correspond to the composite cryogel (CC-Bio). (i)
Force–strain proﬁles obtained after the uniaxial compression of CC and
CC-Bio (the inset corresponds to the photographs of CC-Bio before and
after compression).
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noted with the increased wall thickness (by almost 40%), yield-
ing a flexible, yet strong material (Fig. 1i). These features
match those of tissues for targeted implantation sites, which
are rigid but not fragile. Importantly, the mechanical perform-
ance of the cryogels was evaluated under dry conditions,
which is important as far as implantation and early perform-
ance are concerned. However, wet and cycled wet/dry con-
ditions may change the mechanical performance of the
materials. This has been partially discussed for cryogels pre-
pared from CNC, which showed a near 2-fold decrease in com-
pression strength after three wet cyclic measurements.22
Additionally, in our recent report we investigated the compres-
sive strength organic–inorganic composite materials (SiO2/
CNF) under several harsh conditions.37 We showed that the
mechanical performance of the composites decreased under
wet conditions, but they remained similar after 5 wetting-
drying cycles. It is reasonable to expect that the CNF/bioactive
glass materials prepared herein behave similarly.
The prepared cryogels were exposed to SBF, revealing a dras-
tically diﬀerent behavior as far as hydroxyapatite formation is
concerned (Fig. 2). First, we compared the Fourier-transform
infrared (FTIR) spectra of pure CNF cryogels (CC), pure bio-
active glass, and composite cryogels (CC-Bio) before and after
immersion in SBF (see ESI Discussion S3†). The CC-Bio cryo-
gels displayed extensive formation of carbonated apatite layers,
as can be concluded from the increased signal of crosslinked
uSi–O–Siu at 1030 cm−1 and the reduction of the Si-NBO,
non-bridging oxygen absorption. Such eﬀects are related to the
formation of a silica gel layer on the fibrils and the partial dis-
solution of the bioactive glass, which occurs by ion exchange
of Ca2+ and Na+ from the mineral network with H3O
+ from the
SBF solution.24 Furthermore, hydroxyapatite formation was
confirmed by X-ray photoelectron spectroscopy (XPS; ESI
Discussion S4 and Fig. S4–S7†). Principally, the formation of
the apatite layer was verified by the significant changes in the
relative concentration of P and Ca species on the surface of
CC-Bio after immersion in SBF. These changes only occurred
for the cryogel containing bioactive glass. Furthermore, scan-
ning electron microcopy (SEM) images (Fig. 2b–e) revealed the
typical “cauliflower” morphology of hydroxyapatite, only
observed in CC-Bio (Fig. 2e) upon immersion in SBF. The CNF
framework was coated with hydroxyapatite, resulting in miner-
alized architectures with rough and less-ordered structures.
The apatite layer is chemically and structurally equivalent to
the mineral phase in bone, which improves the interfacial
bonding between the scaﬀolds and bone tissues.38
Additionally, the inherent rough surface of the apatite layer
favors key cell functions in bone tissue engineering.
Another important aspect for bone tissue application is the
release of ions, which activates the expression of the osteo-
genic genes25 and stimulates angiogenesis.27 Angiogenesis is
of critical importance in tissue regeneration.39,40 The improve-
ment of vascularization allows gas exchange and nutrient
transport to osteoblast cells, which are needed for repair of
large bone defects.41,42 Moreover, angiogenesis may lead to the
recruitment of stem cells to the injured site and their orien-
tation to the osteoblastic lineage.43 In this context, scaﬀolds
play an important role, especially in adequate vascularization
at the defect site and consequently in bone regeneration.44 It
has been demonstrated that 30–40 μm is the minimum porosity
required for gas exchange and nutrient transport in the scaﬀold
through the blood vessel.45 A pore size of about 160–270 μm
has been reported to facilitate neovascularization.46 Several
strategies to promote angiogenesis have been developed to
support the successful treatment of large bone defects,47,48
including treatment using diﬀerent ions.27–30 Although not fully
investigated, we suggest that the CNF/bioactive glass addresses
aspects related to the structure–biology relationship.
The cellulosic framework, by itself, is not a source of ions,
making it mandatory the use of an additional phase, in this
case the bioactive glass, for eﬀective bone regeneration. We
used inductively coupled plasma (ICP) spectroscopy to quanti-
tatively assess the dissolution products of the CC-Bio cryogel
during immersion in HEPES solution (Fig. 2f). The character-
istic cascade of events involving the bioactive glass was con-
firmed, in line with the events described by Hench, who
studied the mechanisms for biomineralization.49 The Na+ and
Ca2+ release profiles plateaued after 720 min at 363 ± 13 and
214 ± 1 ppm, respectively. This behavior suggests the mainten-
ance of the vitreous structure of the mineral phase in the
cryogel, i.e., a rapid exchange occurred between Na+/Ca2+ from
the glass network and H3O
+ from solution, which is ascribed
to the partial surface dissolution of the bioactive glass. The
subsequent biomineralization implies the loss of soluble silica
and the formation of SiO2-rich layers, acting as nucleation
centers for the apatite phase. The formation of the silica gel
layer and the solubilization of the glassy phase present in the
Fig. 2 (a) FTIR spectra of CC and CC-Bio before and after immersion in
simulated body ﬂuid (SBF) for 7 days. The FTIR spectrum of the pure bio-
active glass was added for comparison purposes. (b–e) Scanning elec-
tron micrographs of (b and d) CC and (c and e) CC-Bio. The images
show the behavior of the samples (b, c) before and (d, e) after 24 h after
immersion in complete culture medium. (f ) Release proﬁles of Ca, Na, P
and Si ions from CC-Bio in HEPES solution at pH 7.40. Na, Ca, Si or P
species were detected in the case of CC. (g) Schematic illustration
showing ﬁbrils with increasingly rough and bioactive hydroxyapatite
after contact with SBF.
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CC-Bio, as assessed by FTIR and XPS, relate to the leaching of
the silicon species. The Si leaching exhibited a similar trend to
that displayed for the release of sodium and calcium ions,
with a plateau at 93 ± 1 ppm. The release profile of phos-
phorus peaked after 1 h of immersion, displaying a maximum
concentration of 7.89 ± 0.03 ppm (approximately the solubility
limit), followed by a dramatic reduction associated with the
precipitation of phosphate species in the form of calcium
phosphate on the surface of CC-Bio.
The in vitro osteogenic ability of the cryogels was evaluated
(Fig. 3). Red stained biomineralized nodules, which corres-
pond to the extracellular matrix rich in calcium, were only
observed for cells cultured in the presence of CC-Bio (Fig. 3c
and d). Such calcium deposits are related to the increase of the
alkaline phosphatase (ALP) mRNA expression that is usually
followed by an increase in the bone sialoprotein (BSP) gene
expression.50,51 BSP is tightly associated with bone mineraliz-
ation.52 The CC-Bio composite cryogels performed better as far
as osteogenesis is concerned because of the release of Si, Ca,
P, and Na ions from the mineral phase. This greatly enhances
the expression of the genes associated with the osteoblast pro-
liferation and diﬀerentiation during the formation of the bone
extracellular matrix, thus favoring cell diﬀerentiation.53 In vitro
biocompatibility studies (Fig. S7†) revealed that none of the
cryogels significantly aﬀected the metabolic activity and
growth of cells; therefore, they can be considered cytocompati-
ble. This is paramount for practical implementations as any
sign of toxicity represents a risk for the recipient organism.
So far, hydroxyapatite (HA) layers have been shown to build
on virtually any surface,54–56 but their presence does not guar-
antee that the material eﬃciently regenerates bone tissues.6
An eﬃcient scaﬀold for bone tissue engineering must
combine the formation of HA with biocompatibility, high poro-
sity, mechanical support suitable for cell functions, controlled
release of angiogenic agents (ions/species) and ability to
stimulate bone diﬀerentiation.57,58 The composite cryogel,
CC-Bio, covered all of the above-mentioned requirements to
act as a scaﬀold for in vivo bone formation. The aforemen-
tioned features encouraged us to investigate the in vivo bone
regeneration using the rat calvarial defect assay.59 We prepared
cryogels with a diameter and thickness of 5 and 1 mm, respect-
ively. A calvarial defect of 5 mm was then created and the cryo-
gels were placed into the defect site (Fig. 4a). The bare calvarial
defect was used as the control. The calvarial bone of the rats
was analyzed by µCT after 56 days of scaﬀold implantation,
revealing substantial bone formation for rats implanted with
the CC-Bio cryogel (Fig. 4d and g). The bone regeneration
reported for the treatment with CC-Bio reached level 3 in the
scale described by Patel et al.60 In this guide, a numeric
ranking of 0 means no bone formation within the defect area,
whereas 4 means bone bridging entirely through the defect at
the longest point. We observed that the length of the defect
was partially regenerated in 56 days when using the CC-Bio
cryogel as the scaﬀold. Quantitative results acquired from the
µCT images (Fig. 4g) showed that a material with the same
X-ray attenuation of the surroundings calvarial bone was
formed within the CC-Bio cryogel (Fig. 4h). The formed tissue
had a higher local density and lower porosity, suggesting the
formation of bone within the composite scaﬀold.
Treatment of large bone defects requires a material with 3D
porous architecture and a robust biological activity, oﬀering a
Fig. 3 Mineralization assay with Alizarin Red staining of MC3T3-E1 cells
cultured in the presence of (a and b) CC and (c and d) CC-Bio.
Mineralization was visualized in cells cultured in the presence of CC-Bio
with basal (c) and osteogenic (d) media, but not in cells cultivated in the
presence of CC. Scale bar: 200 µm.
Fig. 4 Evaluation of the in vivo performance of the cryogels as far as
bone formation is concerned. (a) Photographs of the procedure fol-
lowed in the rat calvarial assay. Note: The in vivo experiments were
approved by the Ethics Research Committee of the University of
Campinas. (b–g) Representative µCT images of rat calvarial after 56 days
of implantation. 3D reconstruction (top row) and 2D slices inside the 3D
image (bottom row). (b and e) Control, (c and f) CC and (d and g)
CC-Bio. Scale bar represents 1 mm. (h) Quantitative results obtained
from µCT imaging of rat calvarial (n = 6). (i) Quantiﬁcation of serum
BMP-2 expressed as a percentage of the control group. * means statisti-
cally diﬀerent by Tukey’s test with a signiﬁcance level of 5%.
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suitable niche for regeneration. The remarkable performance,
as far as bone regeneration is concerned, observed in CC-Bio,
arises from the combined hydroxyapatite growth on the
cryogel and the release of the ions from the bioactive glass.61
The biomineralized cellulose nanofibrils, from HA deposition,
are shown to possess a porous and rough morphology (Fig. 2e
and g) that favored the adhesion of multipotent cells, which
further underwent osteogenic diﬀerentiation. Smooth surfaces
typically stimulate fibroblastic diﬀerentiation of multipotent
cells with further production of type I collagen-rich, fibrous,
connective tissue membranes. In contrast, rough surfaces,
similar to the ones found in the CC-Bio, stimulate diﬀeren-
tiation into the osteoblastic lineage and bone formation.62,63
The ion release stimulates cell diﬀerentiation and therefore
also induces better bone regeneration. It is known that limited
blood supply leads to low bone tissue repair/regeneration and/
or to cell death.40,64–66 This is relevant to angiogenesis, an
issue that was not considered. However, given the expected
blood transport and availability promoted by the composite,
adequate vascularization at the defect site is anticipated, as
shown later.
The interaction between the bioactive glass and the sur-
rounding environment (body fluid) also aﬀects cell
behavior.67,68 As discussed earlier, the dissolution products
from the bioactive glass are expected to stimulate the prolifer-
ation of osteoblasts, inducing insulin-like growth factor II
mRNA expression and protein synthesis.25 The specific ions
released from our proposed material may stimulate over 5-fold
genes related to cell proliferation and osteogenic diﬀeren-
tiation.53 We measured the behavior of one of the most impor-
tant proteins for bone formation, the bone morphogenetic
protein 2 (BMP-2).69 The results demonstrated an increase by
12% of BMP-2 after 56 days of implantation of CC-Bio in
serum (Fig. 4i), which relates to enhanced bone regeneration.
The control and CC counterparts behaved similarly. The
BMP-2 protein plays an essential role in the formation of a
postnatal skeleton, participating directly in the progression
from osteoprogenitor cells to osteocytes through the regulation
of Runx2 expression.69,70 Moreover, it has been successfully
used to aid the treatment of non-unions.70,71 However, there is
a concern regarding its ideal administration conditions. A
careful evaluation of its dosage is needed as BMP-2 has an ana-
bolic eﬀect on bone, i.e., high doses can promote or worsen
bone cancer.71 Compared to the control group, the results indi-
cated that CC-Bio promoted suﬃcient endogenous release of
BMP-2 to stimulate greater bone formation, with no need of
exogenous therapy, reducing the risk of overdose exposure that
is inherent to this type of treatment.
Lastly, we thoroughly evaluated the systemic biocompatibil-
ity of CC and CC-Bio implants by quantifying the key blood
biochemical markers of toxicity from the liver (TGO – glutamic
oxaloacetic transaminase and TGP – glutamic pyruvic transam-
inase; Fig. 5a and b) and kidneys (creatinine; Fig. 5c).
Histopathological analyses of the recipient’s liver and kidneys
were also performed in order to search for any sign of tissue
damage caused by possible sub-products of the implants
(Fig. 5d–i). The results showed the same levels for the markers
from the control and the cryogels; moreover, no damage was
observed in the organ’s tissue, revealing that the implants
were nontoxic to metabolic and excretory organs such as the
liver and kidneys.
Conclusion
Material advances for the treatment of large bone defects have
included ceramics72 and polymers.73 The inherent brittleness
of the former and low osteo-conductivity of the latter may limit
their separate use, for example, for treatment of calvarial
defects.41 Thus, we propose composites based on nanocellu-
lose/bioactive glass, which optimally combine the features
needed for bone repair. Moreover, the synthesis of such bio-
materials is simple and brings many advantages over the
current strategies, which involve solvent-based, chemical cross-
linking, multi-step fabrication.15,74 We show freeze-casting as a
facile, green, and scalable approach to achieve light, strong,
and highly interconnected bioactive 3D materials for utiliz-
ation in vivo. Moreover, with the recent advances in 3D bio-
printing techniques and additive manufacturing for cellulose
nanostructures,75 the proposed materials can be easily shaped
in any desired form.
The high porosity of the CC-Bio material and its high
specific surface area with high bioactive glass loading prevent
extensive adhesion to the organic support, avoiding erosion or
dispersion in the blood stream. The mineral phase of CC-Bio
Fig. 5 (a–c) Concentration of the biochemical markers of hepatic and
renal damage after 56 postoperative days (n = 6). Data are displayed as
mean and SD. One-way ANOVA and Tukey’s post-test were performed
to compare the experimental and the control groups – no signiﬁcant
diﬀerence was found. Photomicrographs of histological sections of the
(d–f ) liver and (g–i) kidneys of rats from the control (d and g), CC (e and
h) and CC-Bio (f and i) groups after 56 postoperative days. Magniﬁcation
200×. Haematoxylin and eosin staining. No signs of damage were
observed in any of the analyzed organs. These results reveal that the
implants were nontoxic to these organs.
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promotes the release of ions (Si, Ca, P, and Na) while, simul-
taneously, forming rough hydroxyapatite layers upon contact
with body fluids. The combination of high porosity, hydroxy-
apatite formation, and ion release directly aﬀects cell diﬀeren-
tiation as well as increases the release of BMP-2 from the cells
within fractured sections, greatly improving bone formation.
In conclusion, we successfully demonstrated the proposed
strategies by using tests in vitro and in vivo. They show that
light-weight, robust, biocompatible, and bioactive cryogels
comprising cellulose nanofibrils and bioactive glass fit the
requirements of scaﬀolds for bone tissue engineering.
Experimental part
Experimental part is described in the ESI.†
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